Do Consumers Perceive Pharma Industry Innovative?

One of the world’s richest and most powerful American pharma associations, having an equally strong indirect global presence, apparently, expects all concerned to give an emphatic affirmative answer to the above question. Vindication of this thought gets reflected in the … Continue reading

Define And Adapt To Reality: Two Pivotal Pharma Leadership Skills For Sustainable Excellence

Max DePree – a much quoted American businessman and author had once said: “The first responsibility of a leader is to define reality.” While defining the reality within the drug industry today, it makes many industry leaders to ponder, despite … Continue reading

Drug Price Control in India: When A Local Media Goes Against, A Global CEO Doesn’t

‘Variety is the spice of life’, as the good old saying goes. The week, just gone by, was indeed packed with a wide variety of surprises, well encompassing various important areas, some of which are as follows: Effective November 08, … Continue reading

The Stakeholder-Mix Has Changed, But Pharma Marketing Has Not

“We try never to forget that medicine is for the people. It is not for profit. Profits follow, and if we have remembered that, they never fail to appear.” In 1952, George Wilhelm Herman Emanuel Merck, the then President of … Continue reading

Against Pharma Marketing Malpractices: A Gutsy Step

January 7, 2016 edition of ‘The Financial Times (FT)’ reported that responding to escalating pressure on the drug industry, related to its ‘Conflict of Interest’ with the doctors and other related professionals, GlaxoSmithKline (GSK) has decided taking a very unorthodox … Continue reading

Paying For The Best Health Outcomes At The Lowest Possible Cost

“Bayer CEO Dr. Marijn Dekkers is happy to have fair Outcomes-Based Pricing”, reported ‘PharmaTimes’ on December 3, 2014. Dr. Dekkers was quoted saying, “It is okay to be tested on that in the process of price-setting, that is fine, we should … Continue reading

Leading Through The Challenge Of Change: Is Pharma Leadership Too Archaic?

A recent major global survey titled “Testing The Health Of The Pharmaceutical Industry” has revealed that a sizable majority of executives polled, though believe the sector is in good shape, are concerned of its reputation. Interestingly, 73 percent of respondents believe … Continue reading

The ‘TINA Factor’: A Hotspot for Patented Drugs

An article published in a global business magazine on December 5, 2013 mentioned that Marijn Dekkers, the CEO of Bayer AG reportedly has said at the Financial Times Global Pharmaceutical & Biotech Conference held this month that: “Bayer didn’t develop its cancer drug, Nexavar (sorafenib) for … Continue reading